Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has a higher price-to-earnings ratio of 103.55x compared to its average ratio, The 36-month beta value for BMRN is at 0.32. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BMRN is 184.85M, and currently, shorts hold a 1.66% of that float. The average trading volume for BMRN on April 11, 2024 was 1.34M shares.
BMRN) stock’s latest price update
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has seen a rise in its stock price by 1.38 in relation to its previous close of 88.98. However, the company has experienced a 3.95% gain in its stock price over the last five trading sessions. Finbold reported 2024-03-15 that Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors’ trust. Nonetheless, this biotech stock powered through the period, achieving miracle growth and maintaining its decades-long tradition of positive returns.
BMRN’s Market Performance
Biomarin Pharmaceutical Inc. (BMRN) has experienced a 3.95% rise in stock performance for the past week, with a 4.90% rise in the past month, and a -6.16% drop in the past quarter. The volatility ratio for the week is 1.91%, and the volatility levels for the past 30 days are at 1.74% for BMRN. The simple moving average for the past 20 days is 4.76% for BMRN’s stock, with a 1.38% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Wells Fargo repeating the rating for BMRN by listing it as a “Overweight.” The predicted price for BMRN in the upcoming period, according to Wells Fargo is $100 based on the research report published on November 15, 2023 of the previous year 2023.
Bernstein, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $82. The rating they have provided for BMRN stocks is “Mkt Perform” according to the report published on October 23rd, 2023.
BMRN Trading at 3.23% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.13% of loss for the given period.
Volatility was left at 1.74%, however, over the last 30 days, the volatility rate increased by 1.91%, as shares surge +5.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.71% lower at present.
During the last 5 trading sessions, BMRN rose by +3.95%, which changed the moving average for the period of 200-days by -3.52% in comparison to the 20-day moving average, which settled at $86.37. In addition, Biomarin Pharmaceutical Inc. saw -6.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Davis George Eric, who sale 24,602 shares at the price of $88.34 back on Mar 28 ’24. After this action, Davis George Eric now owns 55,856 shares of Biomarin Pharmaceutical Inc., valued at $2,173,341 using the latest closing price.
BIENAIME JEAN JACQUES, the Director of Biomarin Pharmaceutical Inc., sale 1,000 shares at $86.71 during a trade that took place back on Mar 06 ’24, which means that BIENAIME JEAN JACQUES is holding 560,203 shares at $86,713 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.77 for the gross margin
The net margin for Biomarin Pharmaceutical Inc. stands at 0.07. The total capital return value is set at 0.02. Equity return is now at value 3.51, with 2.54 for asset returns.
Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.15. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 8.9.
Currently, EBITDA for the company is 261.98 million with net debt to EBITDA at -2915.04. When we switch over and look at the enterprise to sales, we see a ratio of -304.59. The receivables turnover for the company is 3.82for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.51.
Conclusion
In conclusion, Biomarin Pharmaceutical Inc. (BMRN) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
